At EG427 our unique, non-replicative Herpes Simplex Virus type 1 (HSV-1) based vector platform delivers, with pinpoint precision, highly selective, durable expression of disease modifying transgenes for use in the treatment of peripheral nervous system disorders and beyond. Our lead asset EG110A, for the treatment of neurogenic bladder dysfunction, is expected to be in the clinic by early 2024. Our revolutionary approach to the treatment of this disease aims at providing patients with a comprehensive, long-term solution to their bladder management, through a highly selective molecular biology approach overcoming the drawbacks of current standard of care. Our HQ and labs are in Paris, France, where we were founded in 2019. We have raised over USD 15 million, including from our Series A in 2021.
View Top Employees from EG 427Employees | 20 (7 on RocketReach) |
Founded | 2019 |
Address | 29, Rue du Faubourg Saint-Jacques, Paris, Île-de-France 75014, FR |
Industry | Biotechnology Research |
Looking for a particular EG 427 employee's phone or email?
7 people are employed at EG 427.
EG 427 is based in Paris, Île-de-France.